CytoDyn to Hold Webcast and Live Q/A on December 14 | News
VANCOUVER, Wash., Dec. 10, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Firm"), a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CytoDyn
CytoDyn to Hold Webcast and Live Q/A on December 14
VANCOUVER, Wash., December 10, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Firm"), a late-stage biotechnology firm creating Leronlimab, a CCR5 antagonist with potential for a number of therapeutic indications,…
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically…
VANCOUVER, Washington - (BUSINESS WIRE) - CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Firm"), a late-stage biotechnology firm creating Leronlimab, a CCR5 antagonist with potential for a number of therapeutic indications,…
CytoDyn Submits the First of Three Main Sections of HIV BLA
The second a part of three giant elements of BLA (CMC half) might be submitted shortly Medical part (final half for finishing the BLA) is predicted to be submitted within the first quarter of 2022 VANCOUVER, Wash., Nov. 16, 2021 (GLOBE…
CytoDyn Reminds Stockholders to Register 24 hours before
The administration crew will current the longer term technique of the corporate VANCOUVER, Wash., Nov. 16, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Firm"), a late-stage biotechnology firm creating Leronlimab,…
CytoDyn Announces Preliminary Results from 2021 Annual Meeting | Nation/World
VANCOUVER, Wash. - (BUSINESS WIRE) - Dec. November 2021--CytoDyn Inc.…
CytoDyn Announces Preliminary Results from 2021 Annual Meeting | National Business
VANCOUVER, Wash. - (BUSINESS WIRE) - Dec. November 2021--CytoDyn Inc.…
CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized…
The second a part of three massive elements of BLA (CMC half) can be submitted shortlyScientific part (final half for finishing the BLA) is anticipated to be submitted within the first quarter of 2022VANCOUVER, Wash., Nov. 16, 2021 (GLOBE…
CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized…
The second a part of three massive components of BLA (CMC half) will likely be submitted shortlyScientific…
CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized…
The second a part of three massive elements of BLA (CMC half) shall be submitted shortlyMedical part (final…